Status:

UNKNOWN

Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients

Lead Sponsor:

Fondazione IRCCS Policlinico San Matteo di Pavia

Collaborating Sponsors:

Merck Sharp & Dohme LLC

Menarini Group

Conditions:

Marfan Syndrome

Eligibility:

All Genders

12-55 years

Phase:

PHASE3

Brief Summary

The major clinical problems in patients with Marfan Syndrome (MFS) are aortic root dilation (ARD), dissection and rupture. Although the available treatments (beta-blockers, BBs) improve the evolution ...

Detailed Description

Marfan Syndrome is a rare disease (1:5000)(MIM#154700) caused by mutations of the Fibrillin 1 (FBN1) gene. The major clinical problem is aortic aneurysm with risk of dissection when root diameter is 5...

Eligibility Criteria

Inclusion

  • Diagnosis of MFS: Ghent criteria and genetically proven defect of the FBN1 gene
  • Age: 12 months to 55 years
  • BSA-adjusted aortic z score = or \>2 measured at the level of the sinuses of Valsalva at baseline according to Roman's method, or absolute aortic root diameter \>38mm for females and \>40 mm for males

Exclusion

  • Prior aortic surgery and/or dissection
  • Aortic root diameter at the level of the sinuses of Valsalva 5 cm
  • Planned aortic surgery within 6 months of enrollment for a rate of ARD progression\>5 mm/year even in pts with ARD less than 5 cm
  • Clinical or molecular diagnosis of non-MFS connective tissue diseases sharing some features with MFS (Shprintzen-Goldberg syndrome or Loeys-Dietz syndromes)
  • Un-renounceable therapeutic (systemic hypertension, arrhythmia, ventricular dysfunction, valve regurgitation) use of drugs such as ACE inhibitors, BBs, or calcium-channel blockers
  • Known side-effects while taking an ARB or a BB
  • Intolerance to ARB that resulted in termination of therapy
  • Intolerance to BB that resulted in termination of therapy
  • Renal dysfunction (creatinine level more than upper limit of age-related normal values)
  • Diabetes mellitus
  • Pregnancy or planned pregnancy within 48 months of enrollment
  • Technical limitations for the imaging studies including poor acoustic windows with limits the accurate measurement of aortic root
  • Asthma.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2013

Estimated Enrollment :

291 Patients enrolled

Trial Details

Trial ID

NCT00683124

Start Date

July 1 2008

End Date

July 1 2013

Last Update

July 22 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

IRCCS Foundation San Matteo Hospital

Pavia, Italy, 27100